Jiri Aubrecht
Takeda (United States)(US)
Publications by Year
Research Areas
Biosimilars and Bioanalytical Methods, Computational Drug Discovery Methods, Health Systems, Economic Evaluations, Quality of Life, Inflammatory Bowel Disease, Pharmacogenetics and Drug Metabolism
Most-Cited Works
- → Discovery of Two Clinical Histamine H 3 Receptor Antagonists: trans - N -Ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans -3-Fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]- N -(2-methylpropyl)cyclobutanecarboxamide (PF-03654764)(2011)107 cited
- → Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact(2010)87 cited
- → What evidence do we need for biomarker qualification?(2017)75 cited
- → Chemical Structure-Based and Toxicogenomic Models(2015)9 cited
- → Assessment of Vedolizumab Disease‐Drug‐Drug Interaction Potential in Patients With Inflammatory Bowel Diseases(2020)7 cited
- → S0876 Assessment of Vedolizumab Disease-Drug-Drug Interaction in Patients With Inflammatory Bowel Diseases(2020)1 cited
- → Application of emerging safety biomarkers in drug development(2016)